1
|
Nava-Molina L, Uchida-Fuentes T, Ramos-Tovar H, Fregoso-Padilla M, Rodríguez-Monroy MA, Vega AV, Navarrete-Vázquez G, Andrade-Jorge E, Villalobos-Molina R, Ortiz-Ortega R, Vilches-Flores A. Novel CB1 receptor antagonist BAR-1 modifies pancreatic islet function and clinical parameters in prediabetic and diabetic mice. Nutr Diabetes 2020; 10:7. [PMID: 32132523 PMCID: PMC7055595 DOI: 10.1038/s41387-020-0110-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 01/02/2020] [Accepted: 01/16/2020] [Indexed: 01/24/2023] Open
Abstract
BACKGROUDS Cannabinoid receptor antagonists have been suggested as a novel treatment for obesity and diabetes. We have developed a synthetic cannabinoid receptor antagonist denominated BAR-1. As the function and integrity of a β-cell cellular structure are important keys for diabetes onset, we evaluated the effects of pharmacological administration of BAR-1 on prediabetic and diabetic rodents. METHODS CD-1 mice fed a hypercaloric diet or treated with streptozotocin were treated with 10 mg/kg BAR-1 for 2, 4 or 8 weeks. Body weight, oral glucose tolerance test, HbA1c, triglycerides and insulin in serum were measured. In isolated islets, we evaluated stimulated secretion and mRNA expression, and relative area of islets in fixed pancreases. Docking analysis of BAR-1 was complemented. RESULTS BAR-1 treatment slowed down weight gain in prediabetic mice. Fasting glucose-insulin relation also decreased in BAR-1-treated mice and glucose-stimulated insulin secretion was increased in isolated islets, without effects in oral test. Diabetic mice treated with BAR-1 showed a reduced glucose and a partial recovery of islet integrity. Gene expression of insulin and glucagon showed biphasic behaviour, increasing after 4 weeks of BAR-1 administration; however, after 8 weeks, mRNA abundance decreased significantly. Administration of BAR-1 also prevents changes in endocannabinoid element expression observed in prediabetic mice. No changes were detected in other parameters studied, including the histological structure. A preliminary in-silico study suggests a close interaction with CB1 receptor. CONCLUSIONS BAR-1 induces improvement of islet function, isolated from both prediabetic and diabetic mice. Effects of BAR-1 suggest a possible interaction with other cannabinoid receptors.
Collapse
Affiliation(s)
- Lesly Nava-Molina
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Toyokazu Uchida-Fuentes
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Héctor Ramos-Tovar
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Martha Fregoso-Padilla
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Marco Aurelio Rodríguez-Monroy
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Ana V Vega
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Gabriel Navarrete-Vázquez
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos. Av. Universidad 1001, Chamilpa, C.P., 62209, Cuernavaca, Morelos, Mexico
| | - Erik Andrade-Jorge
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Rafael Villalobos-Molina
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Ricardo Ortiz-Ortega
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico
| | - Alonso Vilches-Flores
- Unidad de Biomedicina, FES Iztacala, Universidad Nacional Autónoma de México. Av. de Los Barrios 1, Los Reyes Iztacala, C.P., 54090, Tlalnepantla, Mexico.
| |
Collapse
|